Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... September 17, 2020 Hormone therapy gets green light for advanced prostate cancer September 14, 2021 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 Load more HOT NEWS Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... Genetic Counseling for Hereditary Breast Cancer: What People With a Family... Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for...
